Keywords: Hepatitis c, Telaprevir, Boceprevir, USA, Gastroenterologists
Larger proportion of hepatitis C non-responder patients in USA will get telaprevir therapy than boceprevir, study shows
Article | 20 January 2010
US gastroenterologists will treat a larger proportion of treatment non-responder hepatitis C patients with Vertex/Tibotec/Mitsubishi Tanabe’s telaprevir ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
